Logo Image

Adam M. Brufsky, MD, PhD

Articles by Adam M. Brufsky, MD, PhD

107 Updated Results and an Exploratory Analysis of ESR1 Mutations (ESR1m) Circulating Tumor DNA (ctDNA) Dynamics From SERENA-6, a Phase III Trial of Camizestrant + CDK4/6 Inhibitor (CDK4/6i) for Emergent ESR1m During First-Line (1L) Endocrine-Based Therapy and Ahead of Disease Progression in Patients With HR+/HER2– Advanced Breast Cancer (ABC)

ByAdam M. Brufsky, MD, PhD,François-Clément Bidard,Erica L. Mayer, MD, MPH,Yeon Hee Park,Wolfgang Janni,Cynthia X. Ma, MD, PhD,Massimo Cristofanilli, MD,Giampaolo Bianchini,Kevin Kalinsky, MD, MS,Hiroji Iwata,Stephen Chia,Peter A. Fasching,Zbigniew Nowecki,Javier Pascual,Einav Nili Gal-Yam,Wei-Pang Chung,Seock-Ah Im,Alberto Zambelli,Florence Dalenc,Mafalda Oliveira,Steven Fox,Manuel Selvi Miralles,Christopher Morrow,Cynthia Huang Bartlett,Nicholas C. Turner, MD

131 Primary Results From ASCENT-03: A Randomized Phase 3 Study of Sacituzumab Govitecan (SG) vs Chemotherapy (Chemo) in Patients (pts) With Previously Untreated Advanced Triple-Negative Breast Cancer (TNBC) Who Are Unable to Receive PD-(L)1 Inhibitors (PD-[L]1i)

ByJavier Cortés, MD,Aditya Bardia, MD, MPH, FASCO,Kevin Punie,Carlos Barrios,Sara A. Hurvitz, MD,Andreas Schneeweiss, MD,Joohyuk Sohn,Eriko Tokunaga,Adam M. Brufsky, MD, PhD,Yeon Hee Park,Binghe Xu,Roberto Hegg,Mafalda Oliveira,Alessandra Fabi,Natalya Vaksman,Theresa Valdez,Xinrui Zhang,Catherine Lai, MD, MPH,Sara M. Tolaney, MD, MPH

8 TiP Randomized, Multicenter, Phase 3 Study to Evaluate the Combination of Enobosarm and Abemaciclib Compared With Estrogen-Blocking Agent for the Second-Line Treatment of AR+, ER+, HER2– Metastatic Breast Cancer in Patients Who Have Previously Received Palbociclib and an Estrogen-Blocking Agent Combination Therapy

ByElgene Lim, MBBS, FRACP, PhD,Adam M. Brufsky, MD, PhD,Hope S. Rugo, MD,Charles L. Vogel, MD, FACP,Joyce A. O’Shaughnessy,Robert H. Getzenberg,K. Gary Barnette,Domingo Rodriguez,Mitchell Steiner,Hannah M. Linden, MD

Latest Updated Articles